Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.
Case Based Peer Perspectives
A discussion on the management of a 64-year-old man with differentiated thyroid cancer, with special consider of the phase 3 SELECT trial regimen.
Medstar Georgetown University Hospital’s Dr Stephen Liu shares impressions on the way a 57-year-old man with ALK-positive metastatic non–small cell lung cancer was managed, highlighting the rationale for using a second-generation ALK inhibitor as treatment.
Lori Wirth, MD, provides insight on the case of a 67-year-old woman with differentiated thyroid cancer and examines the management of radioiodine-refractory disease.
An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.
Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.
Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.
Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.
Pierre Gholam, MD, provides insight on the case of a 61-year-old man with stage 4 hepatocellular carcinoma and evaluates current treatment options on TKIs.
Margaret von Mehren, MD, describes the rationale for treating a man with GIST with ripretinib as fourth-line therapy.
Christopher Flowers, MD, describes the management of an elderly patient with relapsed follicular lymphoma using newer novel therapy.
Kami Maddocks, MD, reviews the case of a 76-year-old woman with stage 4 mantle cell lymphoma and evaluates the role of BTK inhibitors in the treatment of relapsed/refractory disease.
Expert perspectives on the identification and management of metastatic castrate-sensitive prostate cancer in a 67-year-old man.
Danielle M. Brander, MD, remarks on the appropriateness for targeted therapy as a treatment option for a 73-year-old man with relapsed chronic lymphocytic leukemia.
Anthony El-Khoueiry, MD, provides insight on the case of a 69-year-old man with stage 4 hepatocellular carcinoma and evaluates current and emerging treatment options.
Evan Y. Yu, MD, discusses the case and subsequent palliative treatment plan for a patient with metastatic castration-resistant prostate cancer.
Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases.
Ajay K. Gopal, MD, discusses the rationale for treating a 69-year-old woman with high-risk follicular lymphoma with a PI3-kinase inhibitor in the third-line setting.
Corey S. Cutler, MD, MPH, FRCPC, provides insight on the case of a 49-year-old man with chronic GVHD and reviews current and emerging treatment options for disease management.
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.
Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.
Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.
Usama Gergis, MD, presents the case of a 61-year old man with GvHD, and provides an overview of available treatment options for similar patients, with consideration of the REACH1, REACH2, and GRAVITAS-301 trial regimens.
Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer.
A 59-Year-Old Woman With HER2+ De Novo Metastatic Breast Cancer
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
A 54-Year-Old Woman With Stage 2 HER2+ Breast Cancer
A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC